Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVO.L Regulatory News (DVO)

  • There is currently no data for DVO

Trading Update

17 Jan 2020 07:00

RNS Number : 0947A
Devro PLC
17 January 2020
 

For immediate release 17 January 2020

Devro plc

 

Trading update

 

Devro plc ("Devro" or the "Group"), one of the world's leading manufacturers of collagen products for the food industry, issues the following trading update for the year ended 31 December 2019.

 

Full year edible collagen volumes were flat, with the Group delivering overall volume growth of 1% in the second half ("H2"). Slightly lower than anticipated H2 volumes, less favourable country mix combined with a smaller than expected FX benefit due to the strengthening of sterling means we now expect to report underlying operating profit for the year in the range of ÂŁ39 - ÂŁ40 million1.

 

Devro continues to execute its growth plans as set out in its "3Cs strategy", defending and building upon its strong market positions in mature markets2 and targeting to increase its share in emerging markets3. After a slower start in the first half of 2019 overall volumes in emerging markets grew 13% in the second half and 7% for the full year. Whilst overall volumes in North America grew 7%, growth during Q4 was not as strong as expected, specifically impacted by a longer than anticipated Christmas shutdown at a key customer. Market conditions in Japan and Europe continued to be challenging as previously guided. In Europe, we saw weak market sentiment, with lower promotional activity due to higher pork prices and the impact of de-stocking by some of our distributor partners, which we expect to continue into H1 2020. As a result, overall sales in mature markets declined 3% in the year.

 

Cost saving initiatives continued to deliver well and we will achieve £7m savings in FY 2019. Leverage at the year-end improved following positive working capital movements and we expect to report covenant net debt / covenant EBITDA of less than 2x as at 31 December 2019.

 

Our proposed plans for the closure of the Bellshill site in Scotland remain on track.

 

In 2020 we expect to achieve strong volume growth in emerging markets. In our mature markets we expect good volume growth in the North American snacking market and, whilst we anticipate a continuation of the challenging market conditions in Europe (particularly in the first half of 2020), we expect overall Group volumes to be ahead of 2019.

 

Devro will announce its results for the year ended 31 December 2019 on 4 March 2020.

 

 

Contacts:

 

Devro plc

Rutger Helbing

Chief Executive Officer

Tel: 020 3865 7637

Jackie Callaway

Chief Financial Officer

 

 

FTI Consulting

Richard Mountain / Nick Hasell

 

Tel: 020 3727 1340

1 Unaudited

2 Devro mature markets include: North America, Continental EU, UK & Ireland, Japan, Australia & NZ

3 Devro emerging markets include: Latin America, Russia & East, Middle East & Africa, South East Asia, China

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTSFIFUMESSEDF
Date   Source Headline
24th Mar 20174:00 pmRNS2016 Annual Report
15th Mar 20175:14 pmRNSHolding(s) in Company
6th Mar 20177:00 amRNSNotification of Board changes
6th Mar 20177:00 amRNSFinal Results
21st Feb 20172:43 pmRNSHolding(s) in Company
25th Jan 20174:36 pmRNSHolding(s) in Company
11th Jan 20177:00 amRNSYear End Trading Update
21st Dec 20167:00 amRNSAppointment of Non-Executive Director
8th Dec 20164:52 pmRNSDirector/PDMR Shareholding
8th Dec 20164:15 pmRNSDirector/PDMR Shareholding
7th Dec 20164:32 pmRNSDirector/PDMR Shareholding
25th Nov 20163:01 pmRNSDirector/PDMR Shareholding
24th Nov 20163:14 pmRNSBlock listing Interim Review
23rd Nov 20161:32 pmRNSDirector/PDMR Shareholding
14th Nov 201611:36 amRNSDirector/PDMR Shareholding
10th Nov 20164:12 pmRNSDirector/PDMR Shareholding
10th Nov 20164:07 pmRNSDirector/PDMR Shareholding
10th Nov 201610:51 amRNSDirector/PDMR Shareholding
10th Nov 20167:00 amRNSTrading Update
21st Sep 20165:05 pmRNSHolding(s) in Company
18th Aug 20162:24 pmRNSDirector/PDMR Shareholding
18th Aug 20162:23 pmRNSDirector/PDMR Shareholding
11th Aug 201610:41 amRNSHolding(s) in Company
8th Aug 20162:15 pmRNSDirector/PDMR Shareholding
3rd Aug 20167:00 amRNSHalf-year Report
21st Jul 20163:53 pmRNSHolding(s) in Company
30th Jun 20167:00 amRNSTotal Voting Rights and Share Capital
23rd Jun 20163:16 pmRNSDirector/PDMR Shareholding
10th Jun 201610:18 amRNSHolding(s) in Company
25th May 20165:38 pmRNSHolding(s) in Company
24th May 201611:53 amRNSBlock listing Interim Review
23rd May 20163:33 pmRNSDirector/PDMR Shareholding
13th May 20163:33 pmRNSDirector Declaration
5th May 20164:23 pmRNSHolding(s) in Company
28th Apr 20163:54 pmRNSDirector/PDMR Shareholding
27th Apr 20164:45 pmRNSResults of Annual General Meeting
27th Apr 20167:00 amRNSTrading Update
8th Apr 20163:33 pmRNSNotification of Transactions of Directors
30th Mar 20167:00 amRNSAnnual Financial Report
29th Mar 201612:35 pmRNSFurther re: Group Finance Director Retirement
23rd Mar 201612:52 pmRNSNotification of Transactions of Directors
1st Mar 20167:00 amRNSFinal Results
17th Feb 201610:13 amRNSHolding(s) in Company
9th Feb 201612:56 pmRNSHolding(s) in Company
9th Dec 20157:00 amRNSGroup Finance Director
27th Nov 20154:30 pmRNSNotification of Transactions of Directors
24th Nov 20158:23 amRNSBlock Listing Six Monthly Return
17th Nov 20157:01 amRNSGroup Finance Director Retirement
17th Nov 20157:00 amRNSTrading update
21st Oct 20157:00 amRNSNotice of trading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.